Tags

Type your tag names separated by a space and hit enter

Norgestimate: a clinical overview of a new progestin.
Am J Obstet Gynecol. 1992 Jun; 166(6 Pt 2):1969-77.AJ

Abstract

The efficacy and safety of a new monophasic oral contraceptive, norgestimate/ethinyl estradiol, containing the third-generation progestin, norgestimate (250 micrograms), and ethinyl estradiol (35 micrograms), are reviewed. Norgestimate/ethinyl estradiol demonstrates excellent contraceptive efficacy, with a Pearl index of 0.25. Cycle control is reliable, with a low incidence of breakthrough bleeding and spotting. Because of the minimal androgenicity of norgestimate, norgestimate/ethinyl estradiol has a low impact on carbohydrate and lipid metabolism. It neither reduces the vasodilatory and antiaggregatory prostacyclin nor increases its endogenous antagonist, thromboxane. Norgestimate/ethinyl estradiol has no significant effect on blood coagulation factors. All these characteristics suggest that norgestimate/ethinyl estradiol may be associated with a lower risk of cardiovascular disease than other oral contraceptives currently available. Epidemiologic data, however, are not available, and physicians should be reluctant to prescribe it or any oral contraceptive to patients who have a history of vascular or thrombotic disorders.

Authors+Show Affiliations

Hôpital Lapeyronie, Montpellier, France.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

1605287

Citation

Bringer, J. "Norgestimate: a Clinical Overview of a New Progestin." American Journal of Obstetrics and Gynecology, vol. 166, no. 6 Pt 2, 1992, pp. 1969-77.
Bringer J. Norgestimate: a clinical overview of a new progestin. Am J Obstet Gynecol. 1992;166(6 Pt 2):1969-77.
Bringer, J. (1992). Norgestimate: a clinical overview of a new progestin. American Journal of Obstetrics and Gynecology, 166(6 Pt 2), 1969-77.
Bringer J. Norgestimate: a Clinical Overview of a New Progestin. Am J Obstet Gynecol. 1992;166(6 Pt 2):1969-77. PubMed PMID: 1605287.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Norgestimate: a clinical overview of a new progestin. A1 - Bringer,J, PY - 1992/6/1/pubmed PY - 1992/6/1/medline PY - 1992/6/1/entrez KW - Americas KW - Biology KW - Blood Coagulation Effects KW - Carbohydrate Metabolic Effects KW - Cardiovascular Effects KW - Contraception KW - Contraceptive Agents, Estrogen KW - Contraceptive Agents, Female--beneficial effects KW - Contraceptive Agents, Female--contraindications KW - Contraceptive Agents, Female--pharmacodynamics KW - Contraceptive Agents, Progestin KW - Contraceptive Agents--beneficial effects KW - Contraceptive Agents--contraindications KW - Contraceptive Agents--pharmacodynamics KW - Contraceptive Effectiveness KW - Contraceptive Methods KW - Demographic Factors KW - Developed Countries KW - Endocrine System KW - Ethinyl Estradiol KW - Europe KW - Family Planning KW - Fertility KW - Fertility Measurements KW - Germany KW - Glucose Metabolism Effects KW - Hematological Effects KW - Hemic System KW - Lipid Metabolic Effects KW - Lipids KW - Literature Review KW - Metabolic Effects KW - Norgestimate--beneficial effects KW - Norgestimate--contraindications KW - Norgestimate--pharmacodynamics KW - North America KW - Northern America KW - Oral Contraceptives KW - Oral Contraceptives, Combined KW - Pearl's Formula KW - Physiology KW - Population KW - Population Dynamics KW - Pregnancy Rate KW - Prostaglandins KW - United States KW - Use-effectiveness KW - Western Europe SP - 1969 EP - 77 JF - American journal of obstetrics and gynecology JO - Am J Obstet Gynecol VL - 166 IS - 6 Pt 2 N2 - The efficacy and safety of a new monophasic oral contraceptive, norgestimate/ethinyl estradiol, containing the third-generation progestin, norgestimate (250 micrograms), and ethinyl estradiol (35 micrograms), are reviewed. Norgestimate/ethinyl estradiol demonstrates excellent contraceptive efficacy, with a Pearl index of 0.25. Cycle control is reliable, with a low incidence of breakthrough bleeding and spotting. Because of the minimal androgenicity of norgestimate, norgestimate/ethinyl estradiol has a low impact on carbohydrate and lipid metabolism. It neither reduces the vasodilatory and antiaggregatory prostacyclin nor increases its endogenous antagonist, thromboxane. Norgestimate/ethinyl estradiol has no significant effect on blood coagulation factors. All these characteristics suggest that norgestimate/ethinyl estradiol may be associated with a lower risk of cardiovascular disease than other oral contraceptives currently available. Epidemiologic data, however, are not available, and physicians should be reluctant to prescribe it or any oral contraceptive to patients who have a history of vascular or thrombotic disorders. SN - 0002-9378 UR - https://www.unboundmedicine.com/medline/citation/1605287/Norgestimate:_a_clinical_overview_of_a_new_progestin_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0002-9378(92)91397-S DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.